Johnson & Johnson (JNJ) has finally broken out on the upside. Prices are retesting the highs established back in 2017 and 2018. Let's check out our favorite set of charts and indicators to see how this pharma powerhouse can climb in the first quarter of 2020.
More from Investing
No news can explain the action -- whether the bears believe it or not.
The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.
Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.